Business · Companies · 11 hrs ago
Syngenta targets valuation of at least $66 billion in Hong Kong IPO
Syngenta, a Swiss seed and crop-protection company based in Basel, is aiming for a Hong Kong listing early next year.
Its advisers are seeking a valuation of at least $66 billion.
The company is controlled by China’s state-owned Sinochem.
Syngenta reported $4.4 billion in earnings before interest, taxes, depreciation and amortisation in 2025, and a slight increase is expected this year.
The company previously sought a Shanghai listing in 2021 but withdrew its application three years later, citing volatile markets.
Plans for a Hong Kong listing were also delayed by market pressure linked to the Iran war and a change in chief executive.
The proposed IPO would give investors a chance to buy shares, but Syngenta has not commented on the plans.
Syngenta’s advisers are targeting a valuation of at least $66 billion for a planned Hong Kong IPO, according to people familiar with the matter.
The listing is expected to take place early next year, Reuters reported, citing two sources.
Banks have floated a valuation of 15 to 20 times the company’s expected 2026 EBITDA.
Syngenta reported EBITDA of $4.4 billion in 2025, and one source said it was expected to rise slightly this year.
The company, controlled by China’s state-owned Sinochem, declined to comment.
- Who
- Syngenta, the Swiss crop protection and seeds company controlled by China’s Sinochem.
- What
- It is planning a Hong Kong IPO, with advisers targeting a valuation of at least $66 billion.
- When
- The listing is expected early next year. The article was published on October 27, 2026.
- Where
- Hong Kong.
- Why
- Not stated
This story does not have two clearly opposing sides.
Syngenta applied for an IPO in Shanghai.
The company withdrew its Shanghai IPO application, citing volatile markets.
Syngenta considered filing a Hong Kong listing application.
Hengde Qin took over as chief executive from Jeff Rowe.
The Hong Kong listing is expected to take place.
- Target valuation
- At least $66 billion
- Proposed valuation multiple
- 15 to 20 times expected 2026 EBITDA
- 2025 EBITDA
- $4.4 billion
- Headquarters
- Basel
- Controlling shareholder
- Sinochem